P-12 is under clinical development by NeoMatrix Therapeutics and currently in Phase I for Burns. According to GlobalData, Phase I drugs for Burns have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how P-12’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

P-12 overview

P-12 is under development for the prevention and treatment of burns. It is a fibrinoectin derived bioactive peptide applied intravenously. It targets platelet-derived growth factor-BB (PDGF-BB).

NeoMatrix Therapeutics overview

NeoMatrix Therapeutics is a clinical-stage company that develops novel therapeutic agents for the treatment of serious burn injuries and focus on the treatment of severe burns. NeoMatrix Therapeutics is headquartered in Suffolk County, New York, the US.

For a complete picture of P-12’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.